Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because ...

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

While MS isn’t fatal on its own, accompanying complications can shorten life. That said, treatment can significantly decrease the chance of a shortened life span. When it comes to the outlook ...

Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.

Many people who receive an initial diagnosis of relapsing-remitting MS gradually worsen over time, separate from ...

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...

Published extended data from the phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting MS in the peer reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official ...

Decades of subtle health changes went by without answers. When worsening disability led Roger to a multiple sclerosis (MS) ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are ...

UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance. The change of heart ...

NDAQ:TGTX) TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated ...